The Coronavirus Treatment Drugs market is estimated to be valued at US$ 25812.99 Mn or Mn in 2023 and is expected to exhibit a CAGR of 17.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The coronavirus treatment drugs market covers drugs and treatments used for coronavirus disease. Some key product types include antiviral drugs such as remdesivir and favipiravir, immune system modulators, and monoclonal antibody therapies. Coronavirus disease causes respiratory illness and governments and pharma companies are investing heavily in the research and development of effective drugs for the treatment of the disease.
Market Dynamics:
Rising prevalence of coronavirus disease across the globe is driving the demand for effective treatment drugs for the disease. According to WHO, there have been over 495 million confirmed cases of coronavirus disease till November 2022. Further, lack of availability of vaccine in underdeveloped and developing countries is also contributing to the spread of the disease. This is expected to boost the coronavirus treatment drugs market over the forecast period. Another factor aiding the market growth is ongoing research and clinical trials for development of new and more effective drugs for coronavirus treatment. For instance, phase 3 clinical trials are underway for various monoclonal antibody therapies such as sotrovimab and bebtelovimab. Positive outcomes of such trials are likely to provide momentum to the market in the coming years.
SWOT Analysis
Strength: The coronavirus treatment drugs market has strong growth potential due to the ongoing pandemic. Major companies are investing heavily in R&D to develop effective treatment drugs. Many potential drugs are in pipeline which can aid recovery.
Weakness: Developing new drugs require extensive clinical trials and approvals which are costly and time taking. Current drugs have shown side effects in some patients. Alternative treatment methods like vaccines are also available.
Opportunity: Increasing cases of new coronavirus variants can boost demand for improved treatment options. Government support and initiatives will provide impetus to firms for research and development activities. Emerging economies present large patient pool and market scope.
Threats: Patent expiration of blockbuster drugs will increase competition. Alternative non-drug therapies may gain traction. Stringent regulations can delay drugs approval or market entry.
Key Takeaways:
The global Coronavirus Treatment Drugs Market Share size is expected to witness high growth, exhibiting CAGR of 17% over the forecast period, due to increasing research investments from pharmaceutical players. Major companies are injecting funds to develop newer treatment options with lower side effects.
Regional analysis: North America dominates the global market, owing to rising cases, strong healthcare infrastructure, and presence of major pharmaceutical manufacturers in the region. However, Asia Pacific is anticipated to manifest the fastest growth due to large patient base, increasing healthcare spending, and growing penetration of global players in emerging economies like India and China
Key players operating in the coronavirus treatment drugs market include Serum Institute of India, Pfizer Inc., AstraZeneca plc., Bharat Biotech International Limited, Cadila Healthcare Limited, Johnson & Johnson, Moderna, GlaxoSmithKline plc., CanSino Biologics, Sinovac Biotech, Novavax, Inc., Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories, and Merck & Co., Inc. These players are involved in various strategic alliances such as mergers, acquisitions, and collaborations to strengthen their market position.
Read More,
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian